Furthermore, for subsequent clinical translation, the individualized combined treatment strategy based on the ITGA2 expression level of E7820 and lenvatinib that we describe is expected to constitute a new breakthrough for improving the treatment of advanced HCC. Here, ITGA2 is linked to hepatocellular carcinoma.